Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | IDH1 | O75874 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6638863 | 0.87 | DPP4 (0.53) | DPP4DPP7DPP8GSK3BIDH1 | |
| SCHEMBL21095681 | 0.84 | DPP4 (0.50) | DPP4DPP7DPP8GSK3BIDH1 | |
| SCHEMBL6125342 | 0.83 | DPP4 (0.48) | DPP4DPP7DPP8GSK3BIDH1 | |
| SCHEMBL402112 | 0.82 | DPP4 (0.51) | DPP4DPP7DPP8GSK3BIDH1 | |
| SCHEMBL8312031 | 0.81 | DPP4 (0.60) | DPP4DPP7DPP8GSK3BIDH1 | |
| SCHEMBL3049238 | 0.81 | HCAR3 (0.51) | DPP4DPP7DPP8GSK3BIDH1 | |
| SCHEMBL4737899 | 0.79 | DPP4 (0.49) | DPP4DPP7DPP8GSK3BIDH1 | |
| SCHEMBL3115089 | 0.78 | CHEK1 (0.52) | DPP4DPP7DPP8GSK3BIDH1 | |
| SCHEMBL14996239 | 0.78 | HCAR3 (0.54) | DPP4DPP7DPP8GSK3BIDH1 | |
| SCHEMBL8313343 | 0.78 | DPP4 (0.56) | DPP4DPP7DPP8GSK3BIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11007162-B2 | Methods of reducing small, dense LDL particles | CYMABAY THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20190298672-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | CYMABAY THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | US | disclosed |
| EP-2346498-B1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | CYMABAY THERAPEUTICS INC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20170304254-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA NV (DE) | 2017-10-26 | — | — | US | disclosed |
| US-20160074473-A1 | EFFECT OF PHOSPHOLIPID COMPOSITION OF RECONSTITUTED HDL ON ITS CHOLESTEROL EFFLUX AND ANTI-INFLAMMATORY PROPERTIES | KINEMED, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| WO-2016019333-A1 | THE EFFECT OF PHOSPHOLIPID COMPOSITION OF RECONSTITUTED HDL ON ITS CHOLESTEROL EFFLUX AND ANTI-INFLAMMATORY PROPERTIES | KINEMED, INC. (US) | 2016-02-04 | — | — | WO | disclosed |
| US-8796313-B2 | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-08-05 | — | — | US | disclosed |
| US-20140213502-A1 | CHEMICAL MODIFICATION OF APOLIPOPROTEIN MIMETIC PEPTIDES FOR THE PRODUCTION OF THERAPEUTIC AGENTS | United States Department of Health and Human Services (US) | 2014-07-31 | — | — | US | disclosed |
| US-8669288-B2 | Lysine salts of 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-03-11 | — | — | US | disclosed |
| US-20070117177-A1 | Nucleic Acid-Based Matrixes for Protein Production | CORNELL RESEARCH FOUNDATION, INC. | 2007-05-24 | — | — | US | disclosed |
| US-20070117808-A1 | Substituted Cycloalkylpyrrolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-24 | — | — | US | disclosed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| WO-2007041112-A2 | DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041076-A2 | 1,2,3,5-TETRAHYDRO-CYCLOPENTAL[C]QUINOLIN-4-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-12 | — | — | WO | disclosed |
| US-20070032430-A1 | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-02-08 | — | — | US | disclosed |
| US-20060058382-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N. V. (BE) | 2006-03-16 | — | — | US | disclosed |
| US-20050124698-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | CYMABAY THERAPEUTICS, INC. | 2005-06-09 | — | — | US | disclosed |
| US-20050107469-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | CYMABAY THERAPEUTICS, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190298672-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | LDLR, APOB, HDLBP | DPP4 314/4885DPP7 393/4885DPP8 470/4885 |
| US-20060058382-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | DPP4 91/4885DPP7 194/4885DPP8 220/4885 |
| US-20050124698-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | DPP4 76/4885DPP7 188/4885DPP8 246/4885 |
| US-20070032430-A1 | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response | APOB, APOL1, GLP1R | DPP4 679/4885DPP7 846/4885DPP8 767/4885 |
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | DPP4 76/4885DPP7 203/4885DPP8 265/4885 |
| US-20070117808-A1 | Substituted Cycloalkylpyrrolones As Allosteric Modulators Of Glucokinase | GCKR, GCK, GALK1 | DPP4 230/4885DPP7 208/4885DPP8 637/4885 |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | GCK, GCKR, GPR119 | DPP4 82/4885DPP7 77/4885DPP8 265/4885 |
| US-11007162-B2 | Methods of reducing small, dense LDL particles | LDLR, APOB, HDLBP | DPP4 314/4885DPP7 393/4885DPP8 470/4885 |
| US-20170304254-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | DPP4 76/4885DPP7 203/4885DPP8 265/4885 |
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | GCK, GCKR, GPR119 | DPP4 96/4885DPP7 103/4885DPP8 374/4885 |
| US-20050107469-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | DPP4 76/4885DPP7 188/4885DPP8 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.